Literature DB >> 23902320

Genetic metabolic polymorphisms and the risk of cancer: a review of the literature.

A D'errico1, E Taioli, X Chen, P Vineis.   

Abstract

Abstract The purpose of this paper is to systematically analyse the design and results of epidemiological studies on the association between various types of cancer (lung, bladder, breast, colon, stomach) and four genetically-based metabolic polymorphisms, involved in the metabolism of several carcinogens (glutathione-S-transferase M1, debrisoquine hydroxylase, N acetyltransferase, aryl hydrocarbon hydroxylase). These inherited polymorphisms usually cause modifications in the quality or quantity of the relevant enzymes. Such enzymes are involved in the activation/inactivation of known carcinogens and seem to modify the extent to which carcinogens interact with DNA in target tissues. Two enzymes, debrisoquine hydroxylase and aryl hydrocarbon hydroxylase, activate procarcinogens to carcinogens (phase I enzymes). The other two, glutathione-S-transferase M1 and N-acetyltransferase, mainly detoxity carcinogenic substances (phase II enzymes). Because of their role as host factors (modulating the action of carcinogens), it has been hypothesized that subjects presenting a specific phenotype for such polymorphisms could be at a greater risk of developing various types of cancer. A number of epidemiological studies have investigated such associations, often with discordant results. We examine and discuss the design of the studies, and present a meta-analysis of the available data.

Entities:  

Year:  1996        PMID: 23902320     DOI: 10.3109/13547509609079352

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  7 in total

1.  Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines.

Authors:  Scott M Langevin; John P A Ioannidis; Paolo Vineis; Emanuela Taioli
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

2.  NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.

Authors:  Montserrat García-Closas; Núria Malats; Debra Silverman; Mustafa Dosemeci; Manolis Kogevinas; David W Hein; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Gemma Castaño-Vinyals; Meredith Yeager; Robert Welch; Stephen Chanock; Nilanjan Chatterjee; Sholom Wacholder; Claudine Samanic; Montserrat Torà; Francisco Fernández; Francisco X Real; Nathaniel Rothman
Journal:  Lancet       Date:  2005 Aug 20-26       Impact factor: 79.321

Review 3.  A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review.

Authors:  Chunming Gong; Xueying Hu; Yong Gao; Yunfei Cao; Feng Gao; Zengnan Mo
Journal:  Med Oncol       Date:  2010-01-23       Impact factor: 3.064

4.  Molecular epidemiology of major depressive disorder.

Authors:  Chikako Kiyohara; Kouichi Yoshimasu
Journal:  Environ Health Prev Med       Date:  2009-01-20       Impact factor: 3.674

5.  Are glutathione S-transferase gene polymorphisms linked to neonatal jaundice?

Authors:  Necati Muslu; Zeynep Nil Dogruer; Gulcin Eskandari; Aytug Atici; Seval Kul; Ugur Atik
Journal:  Eur J Pediatr       Date:  2007-02-22       Impact factor: 3.183

6.  Role of genetic changes in the progression of cardiovascular diseases.

Authors:  S A Sheweita; H Baghdadi; A R Allam
Journal:  Int J Biomed Sci       Date:  2011-12

7.  The role of GSTM1 gene polymorphisms in lung cancer development in Turkish population.

Authors:  Adalet Demir; Sedat Altin; Davut Pehlivan; Mulahim Demir; Fatih Yakar; Ekrem Cengiz Seyhan; Seyyit Ibrahim Dincer
Journal:  J Carcinog       Date:  2007-09-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.